Abstract:Upon viral infection, the interferon (IFN) system triggers potent antiviral mechanisms limiting viral growth and spread. Hence, to sustain their infection, viruses evolved efficient counteracting strategies to evade IFN control. Ebola virus (EBOV), member of the family Filoviridae, is one of the most virulent and deadly pathogen ever faced by humans. The etiological agent of the Ebola Virus Disease (EVD), EBOV can be undoubtedly considered the perfect example of a powerful inhibitor of the host organism immune response activation. Particularly, the efficacious suppression of the IFN cascade contributes to disease progression and severity. Among the EBOVencoded proteins, the Viral Proteins 35 (VP35) and 24 (VP24) are responsible for the EBOV extreme virulence, representing the core of such inhibitory function through which EBOV determines its very effective shield to the cellular immune defenses. VP35 inhibits the activation of the cascade leading to IFN production, while VP24 inhibits the activation of the IFN-stimulated genes. A number of studies demonstrated that both VP35 and VP24 is validated target for drug development. Insights into the structural characteristics of VP35 and VP24 domains revealed crucial pockets exploitable for drug development. Considered the lack of therapy for EVD, restoring the immune activation is a promising approach for drug development. In the present review, we summarize the importance of VP35 and VP24 proteins in counteracting the host IFN cellular response and discuss their potential as druggable viral targets as a promising approach toward attenuation of EBOV virulence.

Defeating Enemy Outside the Border-Development of Viral Entry Inhibitors

Virus engineering: Fighting HIV at its own game.

Virus Entry Inhibitors: Past, Present, and Future

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses

Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade

Ebola Virus Entry: From Molecular Characterization to Drug Discovery

Viral Entry Inhibitors Targeting Six-Helical Bundle Core Against Highly Pathogenic Enveloped Viruses with Class I Fusion Proteins.

Virology research and development of antiviral drugs

Discovery and development of antiviral drugs

Influenza Virus Cell Entry and Targeted Antiviral Development

Triterpenoid-Mediated Inhibition of Virus-Host Interaction: is Now the Time for Discovering Viral Entry/Release Inhibitors from Nature?

Progress in the treatment of and new drug research on Ebola virus disease

Antivirals with common targets against highly pathogenic viruses

Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets

New perspective of small-molecule antiviral drugs development for RNA viruses

Peptide-Based HIV Entry Inhibitors

Blocking Viral Entry: a Complementary Strategy for HIV Therapy

Antiviral Agents against Flavivirus Protease: Prospect and Future Direction

Viral evasion of the interferon response at a glance

Development Of Protein- And Peptide-Based Hiv Entry Inhibitors Targeting Gp120 Or Gp41